AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Entera Bio Reports Q3 FY23 Earnings, FDA Agrees on BMD as EB613 Endpoint
ByAinvest
Friday, Nov 14, 2025 4:16 pm ET1min read
• Entera Bio reports Q3 2025 financial results • FDA agrees on BMD as primary endpoint for EB613 registrational study • EB613 Phase 2 data shows consistent efficacy in osteoporosis patients • Next-gen EB613 on track for Phase 1 initiation in late 2025 • Pre-clinical data for oral OXM in obesity and GLP-2 in short bowel syndrome presented at ENDO2025 and ESPEN
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet